[Rheumatology] OPG-XL was studied by human induced pluripotent stem cells expressing OPG-XL and two isogenic CRISPR/Cas9-corrected controls in cartilage and bone organoids.
[STAR Protocols] This protocol describes how to generate lung organoids from human embryonic stem cells. Lung organoids form by self-assembly in Matrigel and contain lung epithelial cell types.
[Disease Models & Mechanisms] Investigators developed long-term expandable organoid cultures from endometrium found in uterine rudiment horns of Mayer-Rokitansky-Küster-Hauser (MRKH) patients.
[Cell Death & Disease] Inhibition of mitochondrial apoptosis or of Caspase-activated DNAse reduced the number of micronuclei in tumor cell lines as well as the number of chromosomal misalignments in tumor cells and intestinal organoids.
[Fukushima Medical University (MarketScreener)] CancerTools.org, the research tools arm of Cancer Research UK, and the Fukushima Medical University and Summit Pharmaceuticals International announced a new partnership to progress their shared mission of accelerating cancer research. Through this partnership, FMU will maketheir patient derived organoids available to the global cancer research tools community.
[Nature Communications] Researchers showed, by using 16 different stimuli in vitro, that activated dendritic cells in human blood were phenotypically and functionally dichotomous, and pure cultures of type 2 conventional dendritic cells acquired these states upon appropriate stimuli.
[Asahi Kasei] Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet medical needs in patients with autoimmune diseases.
[Genentech] Genentech announced that the US FDA has accepted the company’s supplemental Biologics License Application for Gazyva® for the treatment of systemic lupus erythematosus.
[Nature Communications] In this multicenter, double-blind, Phase IIb trial, 152 patients with active systemic lupus erythematosus were randomized to receive subcutaneous interleukin 2 or placebo every other day for 12 weeks, then weekly for another 12 weeks. Low-dose-IL2 drove the expansion of Tregs and altered Treg/effector T cell ratios.